San Diego based medical software developer CorTechs Labs announced that it has entered into a partnership agreement with multinational pharmaceutical maker Novartis Pharma AG. The two companies will collaborate in further development of Cortechs’ powerful NeuroQuant breakthrough 510(k) cleared software brain volume quantification device that targets identification, measurement and tracking of brain volume loss in multiple sclerosis (MS) patients. NeuroQuant is designed to make quantitative MRI measurement and analysis of MRI images of the human brain and fully automated MRI post-processing capabilities to the physician’s desktop or mobile device, a routine part of clinical practice.
A NeuroQuant report provides neurologists, radiologists, and clinical researchers with a convenient and cost-effective means to quantify atrophy of brain structures to help diagnose a variety of brain disorders, including conditions such as Alzheimer’s disease, epilepsy, multiple sclerosis and traumatic brain injury. It enables clinicians to conduct sophisticated, automated, accurate, and consistent measurements of the whole brain, the left and right thalami and the lateral ventricles using data from 3D T1 MRI images, and targets identification and tracking of neurodegeneration in these sub-cortical structures.
Non-invasive, inexpensive and accurate, NeuroQuant is used to verify Alzheimer’s in patients 50-95, assessment of epilepsy and multiple sclerosis in patients 18 and older, traumatic brain injury in NFL players, boxers and soldiers, and more. Cortechs’ technologies provide physicians with the objective information they need to confirm or refute a projected diagnosis.
NeuroQuant is available both online and as an installed software solution, provides neurologists and radiologists with objective data on brain volume loss and the brain’s changes over time compared with normative values.
“We’re pleased to partner with Novartis to advance the clinical care and assessment of multiple sclerosis worldwide,” says CorTechs Labs’ CEO Guri Stark CorTechs Labs’ CEO Guri Stark, “We believe this partnership will empower clinicians with objective quantitative data, while continuing NeuroQuant’s growth momentum. This, in-turn furthers our vision to establish NeuroQuant as the standard measurement solution for all brain disorders, including Alzheimer’s disease, epilepsy, multiple sclerosis and traumatic brain injury.”
NeuroQuant is the first FDA-cleared and CE marked (a mandatory conformity marking for certain products sold within the European Economic Area) medical device capable of automatically detecting and quantifying human brain atrophy. It provides a convenient and cost-effective means by which neurologists, radiologists, clinical researchers and imaging centers can quantify brain structure atrophy.
NeuroQuant automatically segments and measures volumes of the hippocampus, ventricles and other brain structures and compares these volumes to normal values. Reducing subjectivity in the diagnosis process, Cortechs’ software brings quantified measurements of neurodegeneration directly to the specialist’s desktop.
For data input, NeuroQuant takes a high-resolution 3D T1-weighted sagittal, non-contrast-enhanced MRI scan from a disk or auto-routed from a scanner or PACS server, and after adjusting for distortions, the software identifies and segments multiple brain structures. It then measures their volumes and compares the volumes to a normative database adjusted for age, sex and cranial volume.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?